Biotech Firm Windtree Doubles Down on Crypto With New BNB Plan

Windtree Therapeutics (NasdaqCM: WINT) is pivoting aggressively into digital assets, unveiling a $520 million funding package dedicated almost entirely to BNB crypto acquisitions. The strategy includes a $500 million equity line of credit (ELOC) and a $20 million stock purchase agreement with Build and Build Corp, with 99% of the proceeds allocated to BNB purchases.

According to the announcement, the ELOC underscores Windtree’s ambition to diversify its balance sheet with blockchain-based assets while maintaining its traditional biotech operations. This funding round is part of a broader plan to position Windtree as a hybrid innovator in both healthcare and digital finance.

“We are excited to incorporate these new facilities to enable our future BNB acquisitions as part of our BNB treasury strategy. The opportunity to secure additional funds for purchasing more BNB cryptocurrency is essential to our strategy,” stated Jed Latkin, CEO of Windtree.

Combined with previously announced initiatives, the company expects its BNB commitment to reach as high as $700 million, marking one of the largest corporate treasury strategies focused on a single altcoin.

Windtree stated that these moves aim to strengthen shareholder value, leveraging both the growth potential of BNB and the liquidity of blockchain ecosystems.

免责声明：本文章仅代表作者个人观点，不代表本平台的立场和观点。本文章仅供信息分享，不构成对任何人的任何投资建议。用户与作者之间的任何争议，与本平台无关。如网页中刊载的文章或图片涉及侵权，请提供相关的权利证明和身份证明发送邮件到support@aicoin.com，本平台相关工作人员将会进行核查。